Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

InMed Pharmaceuticals — 14 videos in collection

More on this equity

InMed is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free